Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433290 · ClinicalTrials.gov registry record · Phase 3
Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT00433290 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 256 participants.
The verdict
NCT00433290, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.
Interventions
- DRUG Placebo
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433290
The ClinicalTrials.gov registry entry for NCT00433290 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00433290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00433290 about?
NCT00433290 is a clinical study titled "Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain". The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.
What is the current status of trial NCT00433290?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2007-02. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00433290?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00433290?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.